Status In progress
Process STA pre-2018
ID number 1008

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
14 June 2018 As you will be aware, the Department for Health and Social Care has asked NICE to undertake an appraisal of blinatumomab for treating Philadelphia-chromosome-positive relapsed or refractory acute lymphoblastic leukaemia. Please note that following on from advice received from the company, the timelines for this appraisal remain to be confirmed, whilst regulatory timings are established. NICE will continue to monitor any development and will update interested parties as and when the situation changes.
11 August 2017 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid April 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid June 2018.
22 June 2017 Following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early January 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early March 2018.
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance